Harbeck N - Search Results

1

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R. Harbeck N, et al. J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711169

2

Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients.

Braun S, Harbeck N. Braun S, et al. Among authors: harbeck n. Breast Cancer Res. 2001;3(5):285-8. doi: 10.1186/bcr308. Epub 2001 Jun 28. Breast Cancer Res. 2001. PMID: 11597315 Free PMC article. Review.

3

Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.

Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M, Royer HD. Janz M, et al. Among authors: harbeck n. Int J Cancer. 2002 Jan 20;97(3):278-82. doi: 10.1002/ijc.1610. Int J Cancer. 2002. PMID: 11774277 Free article.

4

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA. Look MP, et al. Among authors: harbeck n. J Natl Cancer Inst. 2002 Jan 16;94(2):116-28. doi: 10.1093/jnci/94.2.116. J Natl Cancer Inst. 2002. PMID: 11792750 Free article.

5

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Harbeck N, Kates RE, Schmitt M. Harbeck N, et al. J Clin Oncol. 2002 Feb 15;20(4):1000-7. doi: 10.1200/JCO.2002.20.4.1000. J Clin Oncol. 2002. PMID: 11844823

6

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Harbeck N, et al. Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417

7

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

8

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Zemzoum I, et al. Among authors: harbeck n. J Clin Oncol. 2003 Mar 15;21(6):1022-8. doi: 10.1200/JCO.2003.04.170. J Clin Oncol. 2003. PMID: 12637466

9

Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.

Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N. Roggel F, et al. Among authors: harbeck n. Recent Results Cancer Res. 2003;162:89-100. doi: 10.1007/978-3-642-59349-9_8. Recent Results Cancer Res. 2003. PMID: 12790324 Review.

10

Advanced statistical methods for the definition of new staging models.

Kates R, Schmitt M, Harbeck N. Kates R, et al. Among authors: harbeck n. Recent Results Cancer Res. 2003;162:101-13. doi: 10.1007/978-3-642-59349-9_9. Recent Results Cancer Res. 2003. PMID: 12790325 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

689 results

Search Page